Hematological toxicities of immune checkpoint inhibitors and the impact of blood transfusion and its microbiome on therapeutic efficacy and recipient’s safety and survival outcome:A systematic narrative appraisal of where we are now!

Gaspar, 2015, Anemia in malignancies: pathogenetic and diagnostic considerations, Hematology, 20, 18, 10.1179/1607845414Y.0000000161 Knight, 2004, Prevalence and outcomes of anemia in cancer: a systematic review of the literature, Am J Med, 116, 11S, 10.1016/j.amjmed.2003.12.008 Madeddu, 2018, Pathogenesis and treatment options of cancer related anemia: perspective for a targeted mechanism-based approach, Front Physiol, 9, 1294, 10.3389/fphys.2018.01294 Abdel-Razeq, 2020, Recent update in the pathogenesis and treatment of chemotherapy and cancer induced anemia, Crit Rev Oncol Hematol, 145, 10.1016/j.critrevonc.2019.102837 Naidoo, 2016, Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies, Ann Oncol, 27, 1362, 10.1093/annonc/mdw141 Davies, 2019, Acute and long-term adverse events associated with checkpoint blockade, Semin Oncol Nurs, 35, 10.1016/j.soncn.2019.08.005 Delanoy, 2019, Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study, Lancet Haematol, 6, e48, 10.1016/S2352-3026(18)30175-3 Demetri, 2001, Anaemia and its functional consequences in cancer patients: current challenges in management and prospects for improving therapy, Br J Cancer, 84 Suppl 1, 31, 10.1054/bjoc.2001.1750 Ludwig, 2001, Symptomatology of anemia, Semin Oncol, 28, 7, 10.1016/S0093-7754(01)90206-4 Huang, 2022, The association between pretreatment anemia and overall survival in advanced non-small cell lung cancer: a retrospective cohort study using propensity score matching, J Cancer, 13, 51, 10.7150/jca.55159 Goubran, 2016, Impact of transfusion on cancer growth and outcome, Cancer Growth Metastas, 9, 1, 10.4137/CGM.S32797 Iqbal, 2017, Red blood cell transfusion and outcome in cancer, Transfus Apher Sci, 56, 287, 10.1016/j.transci.2017.05.014 Opelz, 1973, Effect of blood transfusions on subsequent kidney transplants, Transpl Proc, 5, 253 Petrelli, 2021, Efficacy of immune checkpoint inhibitors in rare tumours: a systematic review, Front Immunol, 12, 10.3389/fimmu.2021.720748 Goubran, 2017, Transfusion-related immunomodulation and cancer, Transfus Apher Sci, 56, 336, 10.1016/j.transci.2017.05.019 Goubran, 2017, The microbiome and transfusion in cancer patients, Transfus Apher Sci, 56, 330, 10.1016/j.transci.2017.05.023 Goubran H., The microbiome and transfusion in cancer patients, International Society of blood transfusion, Plenary State of the Art, Educational Session, Barcelona, Spain, 2020. ISBT science series abstract PL-02–02: 4. Marin-Acevedo, 2019, Immune checkpoint inhibitor toxicities, Mayo Clin Proc, 94, 1321, 10.1016/j.mayocp.2019.03.012 Michot, 2019, Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?, Eur J Cancer, 122, 72, 10.1016/j.ejca.2019.07.014 Davis, 2019, Hematologic complications of immune checkpoint inhibitors, Oncologist, 24, 584, 10.1634/theoncologist.2018-0574 Bergvall, 2014, vigiGrade: a tool to identify well-documented individual case reports and highlight systematic data quality issues, Drug Saf, 37, 65, 10.1007/s40264-013-0131-x Hill, 2018, Autoimmune hemolytic anemia, Hematol Am Soc Hematol Educ Program, 2018, 382, 10.1182/asheducation-2018.1.382 Hwang, 2022, Immunotherapy-associated autoimmune hemolytic anemia, Hematol Oncol Clin North Am, 36, 365, 10.1016/j.hoc.2021.11.002 Hasanov, 2018, Nivolumab-induced cold agglutinin syndrome successfully treated with rituximab, Blood Adv, 2, 1865, 10.1182/bloodadvances.2018019000 Saliba, 2021, Immune-related hematologic adverse events in the context of immune checkpoint inhibitor therapy, Am J Hematol, 96, E362, 10.1002/ajh.26273 Palla, 2016, Autoimmune hemolytic anemia as a complication of nivolumab therapy, Case Rep Oncol, 9, 691, 10.1159/000452296 Schwab, 2016, Development of hemolytic anemia in a nivolumab-treated patient with refractory metastatic squamous cell skin cancer and chronic lymphatic leukemia, Case Rep Oncol, 9, 373, 10.1159/000447508 Tardy, 2017, Autoimmune hemolytic anemia after nivolumab treatment in Hodgkin lymphoma responsive to immunosuppressive treatment. A case report, Hematol Oncol, 35, 875, 10.1002/hon.2338 Kong, 2016, Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma, Melanoma Res, 26, 202, 10.1097/CMR.0000000000000232 Simeone, 2014, Serious haematological toxicity during and after ipilimumab treatment: a case series, J Med Case Rep, 8, 240, 10.1186/1752-1947-8-240 Khan, 2017, Immunotherapy-associated autoimmune hemolytic anemia, J Immunother Cancer, 5, 15, 10.1186/s40425-017-0214-9 Tanios, 2019, Autoimmune hemolytic anemia associated with the use of immune checkpoint inhibitors for cancer: 68 cases from the Food and Drug Administration database and review, Eur J Haematol, 102, 157, 10.1111/ejh.13187 Leaf, 2019, Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors, Am J Hematol, 94, 563, 10.1002/ajh.25448 Brahmer, 2018, National comprehensive cancer network. management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: american society of clinical oncology clinical practice guideline, J Clin Oncol, 36, 1714, 10.1200/JCO.2017.77.6385 Ghanem, 2022, Current challenges of hematologic complications due to immune checkpoint blockade: a comprehensive review, Ann Hematol, 101, 1, 10.1007/s00277-021-04690-x Means, 2016, Pure red cell aplasia, Blood, 128, 2504, 10.1182/blood-2016-05-717140 Gordon, 2009, Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma, Cancer Immunol Immunother, 58, 1351, 10.1007/s00262-008-0627-x Nair, 2016, Immunotherapy-associated hemolytic anemia with pure red-cell aplasia, N Engl J Med, 374, 1096, 10.1056/NEJMc1509362 Yuki, 2017, A case of pure red cell aplasia during nivolumab therapy for cardiac metastatic melanoma, Melanoma Res, 27, 635, 10.1097/CMR.0000000000000392 Le Aye, 2019, Bone marrow findings of immune-mediated pure red cell aplasia following anti-programmed cell death receptor-1 therapy: a report of two cases and review of literature, J Hematol, 8, 71, 10.14740/jh507 Isoda, 2020, Pembrolizumab-induced pure red cell aplasia successfully treated with intravenous immunoglobulin, Intern Med, 59, 2041, 10.2169/internalmedicine.4467-20 Joly, 2017, Thrombotic thrombocytopenic purpura, Blood, 129, 2836, 10.1182/blood-2016-10-709857 Youssef, 2018, Thrombotic thrombocytopenic purpura due to checkpoint inhibitors, Case Rep Hematol, 2018 Ali, 2020, Thrombotic thrombocytopenic purpura induced by immune checkpoint inhibitiors: a case report and review of the literature, Cureus, 12 Dickey, 2020, Pembrolizumab-induced thrombotic thrombocytopenic purpura, J Oncol Pharm Pr, 26, 1237, 10.1177/1078155219887212 Gilbar, 2022, Case reports of acquired thrombotic thrombocytopenic purpura attributed to pembrolizumab, J Oncol Pharm Pr, 10.1177/10781552221088025 Nelson, 2022, Spectrum of immune checkpoint inhibitor anemias: results from a single center, Early-Phase Clin Trials Case Ser Exp J Hematol, 11, 113 King, 2017, Ipilimumab-induced thrombotic thrombocytopenic purpura (TTP), J Immunother Cancer, 5, 19, 10.1186/s40425-017-0224-7 Thomas, 2021, How I treat microangiopathic hemolytic anemia in patients with cancer, Blood, 137, 1310, 10.1182/blood.2019003810 Lafranchi, 2020, Thrombotic thrombocytopenic purpura associated to dual checkpoint inhibitor therapy for metastatic melanoma, CEN Case Rep, 9, 289, 10.1007/s13730-020-00454-0 Lancelot, 2021, Refractory thrombotic thrombocytopenic purpura related to checkpoint inhibitor immunotherapy, Transfusion, 61, 322, 10.1111/trf.16117 Rodeghiero, 2009, Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group, Blood, 113, 2386, 10.1182/blood-2008-07-162503 Shiuan, 2017, Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy, J Immunother Cancer, 5, 8, 10.1186/s40425-017-0210-0 Kanameishi, 2016, Idiopathic thrombocytopenic purpura induced by nivolumab in a metastatic melanoma patient with elevated PD-1 expression on B cells, Ann Oncol, 27, 546, 10.1093/annonc/mdv580 Karakas, 2017, Immune thrombocytopenia induced by nivolumab in a metastatic non-small cell lung cancer patient, Oncol Res Treat, 40, 621, 10.1159/000477968 Haddad, 2022, Cancer Immunol Immunother, 71, 1157, 10.1007/s00262-021-03068-2 Sui, 2018, Risk of hematologic toxicities with programmed cell death-1 inhibitors in cancer patients: a meta-analysis of current studies, Drug Des Devel Ther, 12, 1645, 10.2147/DDDT.S167077 Quirk, 2015, Immune-mediated adverse events of anticytotoxic T lymphocyte-associated antigen 4 antibody therapy in metastatic melanoma, Transl Res, 166, 412, 10.1016/j.trsl.2015.06.005 Jotatsu, 2018, Immune-mediated thrombocytopenia and hypothyroidism in a lung cancer patient treated with nivolumab, Immunotherapy, 10, 85, 10.2217/imt-2017-0100 Mori, 2019, Immune thrombocytopenia induced by nivolumab in a patient with non-small cell lung cancer, Respir Med Case Rep, 28 Trinh, 2019, Management of immune-related adverse events associated with immune checkpoint inhibitor therapy: a minireview of current clinical guidelines, Asia Pac J Oncol Nurs, 6, 154, 10.4103/apjon.apjon_3_19 Rogers, 2021, Management of hematologic adverse events associated with immune checkpoint inhibitors, J Adv Pr Oncol, 12, 392 Zaremba, 2021, Grade 4 neutropenia secondary to immune checkpoint inhibition - a descriptive observational retrospective multicenter analysis, Front Oncol, 11, 10.3389/fonc.2021.765608 Kramer, 2021, Hematological immune related adverse events after treatment with immune checkpoint inhibitors, Eur J Cancer, 147, 170, 10.1016/j.ejca.2021.01.013 Petrelli, 2021, Risk of infection with immune checkpoint inhibitors: a systematic review and meta-analysis, Target Oncol, 16, 553, 10.1007/s11523-021-00824-3 Boegeholz, 2020, Challenges in diagnosis and management of neutropenia upon exposure to immune-checkpoint inhibitors: meta-analysis of a rare immune-related adverse side effect, BMC Cancer, 20, 300, 10.1186/s12885-020-06763-y Mackey, 2006, MAMPs and MIMPs: proposed classifications for inducers of innate immunity, Mol Microbiol, 61, 1365, 10.1111/j.1365-2958.2006.05311.x Geraldo, 2022, The effect of probiotic use on ABO antibody titers, Immunohematology, 38, 55 Païssé, 2016, Comprehensive description of blood microbiome from healthy donors assessed by 16S targeted metagenomic sequencing, Transfusion, 56, 1138, 10.1111/trf.13477 Yang, 2022, Variations in oral microbiome and its predictive functions between tumorous and healthy individuals, J Med Microbiol, 71, 10.1099/jmm.0.001568 Heiss, 1994, Blood transfusion-modulated tumor recurrence: first results of a randomized study of autologous versus allogeneic blood transfusion in colorectal cancer surgery, J Clin Oncol, 12, 1859, 10.1200/JCO.1994.12.9.1859 Amato, 2006, Perioperative blood transfusions for the recurrence of colorectal cancer, Cochrane Database Syst Rev, 2006 Petrelli, 2021, Red blood cell transfusions and the survival in patients with cancer undergoing curative surgery: a systematic review and meta-analysis, Surg Today, 51, 1535, 10.1007/s00595-020-02192-3 Han, 2021, Blood transfusion had no influence on the 5-year biochemical recurrence after robot-assisted radical prostatectomy: a retrospective study, BMC Urol, 21, 160, 10.1186/s12894-021-00926-0 D’Avella, 2020, The effect of packed red blood cell transfusions on the clinical efficacy of immunotherapy, J Immunother Cancer, 8, A180 Mispelbaum, 2022, Red blood cell transfusions impact response rates to immunotherapy in patients with solid malignant tumors, Front Immunol, 13, 10.3389/fimmu.2022.976011 Miller, 2020, Mechanisms and microbial influences on CTLA-4 and PD-1-based immunotherapy in the treatment of cancer: a narrative review, Gut Pathog, 12, 43, 10.1186/s13099-020-00381-6 Gopalakrishnan, 2018, Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients, Science, 359, 97, 10.1126/science.aan4236 Helmink, 2019, The microbiome, cancer, and cancer therapy, Nat Med, 25, 377, 10.1038/s41591-019-0377-7 Gopalakrishnan, 2020, Intervention strategies for microbial therapeutics in cancer immunotherapy, Immunooncol Technol, 6, 9, 10.1016/j.iotech.2020.05.001 Seghatchian, 2022, Spotlight on SARS CoV-2 infection inducing autoimmunity, through the formation of autoantibody to self hemostatic components or to host cells, often leading to severe thrombotic or bleeding events, Transfus Apher Sci Dec, 15 Amiral J., Seghatchian J.: Autoimmune complications of COVID-19 and potential consequences for long-lasting disease syndromes Transfusion Apheresis Science December 2022[ in press].